Kulkarni Samarth's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Nov 13, 2024
- Accession no.
- 0000950170-24-126521
- Filed
- Nov 13, 2024
- Trade date
- Nov 11, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.67M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kulkarni SamarthCIK 0001682019 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Common Shares | SSaleDisposed | −23,121 | $55.43 | −$1,281,597.03 | 203,419 | Direct | |
| Nov 11, 2024 | Common Shares | SSaleDisposed | −6,879 | $56.27 | −$387,081.33 | 196,540 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.